Drug Trial Radar · NCT06001619
Prostate Medication, Metabolism and Gut Microbiota
Last checked: Nov 20, 2026Latest source record: Aug 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 1, 2022
Primary completion
Oct 31, 2024
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Turku University HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PROMED is a prospective, single center translational multiple cohort study to investigate the association of prostate medication and gut microbiota. The main aim is to investigate how prostate hormonal therapy (5-ARI, ADT) affects gut microbiota composition. Aalso study metabolic characteristics in the gut and systemic circulation in men with different medications will be studied. In addition, the effect of gut microbiota on patient's response to medications will be investigated. The medicines used in the study to treat benign prostate hyperplasia are dutasteride and finasteride and a combination of dutasteride and tamsulosin. LHRH antagonist degarelix is used as a medication to treat patients with cancer. The dosages of 5-ARI medication: dutasteride 0,5mg x1 or finasteride 5mg x1 or combination of dutasteride and tamsulosin 0,5/0,4mg x1. The starting dose of LHRH antagonist degarelix is 120mgx2 and the maintenance dose is 80mgx1. The medication for PCa is planned according to the protocol but so that each subject receives degarelix at the beginning of treatment and one month after initiation. Thereafter, the medication is continued according to the clinician's assessment. The study is carried out in Turku University Hospital and University of Turku.
Conditions
- Prostatic Hyperplasia
- Prostate Cancer
Interventions
Prostate hyperplasia medicationDrug
The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.
LhRH-antagonistDrug
The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Gut microbiota signature before 5-ARI therapyTime frame: before starting prostate 5-ARI medication
- Gut microbiota signature after 5-ARI therapyTime frame: 2 months after starting prostate 5-ARI medication
- Gut microbiota signature before ADT (LHRH antagonists).Time frame: before starting prostate degarelix
- Gut microbiota signature after ADT (LHRH antagonists).Time frame: 2 months after starting prostate degarelix
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Turku University Hospital
Turku, Finland · Recruiting
University of Turku
Turku, Finland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.